AI/ML technologies are revolutionizing pharmaceutical formulation by optimizing excipient selection and predicting stability, reducing time and resources needed for development. Poor solubility of ...

Formulation scientists are behind the conversion of active pharmaceutical ingredients (API) into stable, bioavailable, and commercially viable dosage forms, rarely a simple process. Image Credit: ...

In the last 10 years, there has been significant development in computer simulation of pharmaceutical materials, processes and product performance. Gradually, more mechanistically based models are ...

A partnership between Aston University and contract medicine manufacturer Catalent has led to a faster process to identify the best ingredients for optimal medicine formulations, and has been rated as ...

HUNT VALLEY, Md., July 27, 2011 /PRNewswire/ -- Pharmaceutics International, Inc. (Pii), a leading contract development and manufacturing organization, today announced that it has added hot melt ...

This tablet press will provide the facility's Formulation Development Team with an important tool for developing fixed dose combinations and modified release drug delivery. Piramal Pharma Solutions ...

A dearth of new molecules and impending patent cliffs have turned drug-delivery technologies into a hotbed for innovation, with companies desperate to gain an edge over rivals, says Lux Research.

LONDON--(BUSINESS WIRE)--Global procurement intelligence advisory firm, SpendEdge, has announced the release of their ‘Pharmaceutical Formulation Equipment Procurement Research Report.’ The insights ...

The "A Practical Approach to Developing the CMC Package for Veterinary Pharmaceutical Products Training Course (May 7, 2026)" has been added to ResearchAndMarkets.com's offering. Understanding the ...

Small Pharma is evaluating the best way to administer N,N-dimethyltryptamine (DMT) in a therapeutic setting for the treatment of depressive disorders. DMT—the primary psychoactive compound in ...

LYON, France--(BUSINESS WIRE)--MaaT Pharma announced today that it treated its first patient in a Phase 1 clinical trial to evaluate the safety and tolerability of MaaT033, a capsule formulation of ...